This is an excerpt from the above article: which may have already been posted-
"Over the period analysed, no major study or guideline has advocated a change in liothyronine prescribing. Thus, this substantial reduction in prescribing seems to have been largely driven by cost. In view of the concerns raised by patients, this large disparity between CCGs in prescribing liothyronine linked to deprivation status is difficult to justify. Moreover, patients in more affluent areas might be more able to source liothyronine by private prescription, further exacerbating the inequality.